MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-08-2024
Emergent BioSolutions Financial Ratios 2011-2025 | EBS
Annual Financial Ratios Emergent BioSolutions
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.2 | -2.8 | 11.4 | 18.4 | 52.1 | 48.4 | 25.2 | 23.1 | 22.5 | 28.5 | 27.6 | 24.6 | 26.5 |
P/S |
0.1 | 0.5 | 1.4 | 3.6 | 2.6 | 3.9 | 3.7 | 2.4 | 2.7 | 2.3 | 2.8 | 2.1 | 2.2 |
EPS |
-14.8 | -4.2 | 4.1 | 5.8 | 1.1 | 1.2 | 2.0 | 1.3 | 1.6 | 1.0 | 0.9 | 0.7 | 0.7 |
EV (Enterprise Value) |
1.2 B | 1.73 B | 3.27 B | 6.45 B | 3.91 B | 4.14 B | 2.06 B | 1.3 B | 1.48 B | 1.16 B | 819 M | 560 M | 596 M |
EBITDA per Share |
-11.7 | -0.53 | 8.7 | 9.27 | 3.36 | 2.29 | 3.99 | 3.58 | 3.4 | 2.42 | 1.71 | 1.41 | 1.16 |
EV/EBITDA |
7.8 | 12.0 | 20.2 | 32.4 | 11.5 | 8.3 | 10.3 | 11.2 | 12.0 | 9.9 | 12.7 | ||
PEG |
-0.0 | -0.21 | 0.31 | 0.47 | -3.43 | -1.31 | 0.47 | -1.11 | 0.34 | 2.04 | 0.87 | 80.54 | -0.44 |
P/B |
0.2 | 0.4 | 1.6 | 3.9 | 2.6 | 3.0 | 2.3 | 2.0 | 2.1 | 1.9 | 1.8 | 1.3 | 1.5 |
P/CF |
-0.7 | -17.4 | 7.8 | 10.5 | 28.1 | -100.1 | 13.6 | -52.4 | -4001.7 | 12.8 | 15.7 | -40.8 | -15.5 |
ROE % |
-117.13 | -15.25 | 13.62 | 21.08 | 5.01 | 6.20 | 9.05 | 8.68 | 9.53 | 6.64 | 6.36 | 5.32 | 5.52 |
ROA % |
-41.71 | -6.68 | 7.42 | 10.61 | 2.34 | 2.81 | 7.72 | 5.34 | 6.02 | 3.89 | 4.97 | 4.17 | 4.21 |
ROCE % |
-111.87 | -12.25 | 21.19 | 30.22 | 5.41 | 4.43 | 12.81 | 12.21 | 10.17 | 6.81 | 7.51 | 7.88 | 6.75 |
Current Ratio |
1.6 | 1.8 | 2.2 | 2.0 | 3.2 | 3.1 | 4.9 | 4.8 | 5.4 | 4.7 | 4.8 | 4.3 | 3.6 |
DSO |
60.9 | 71.5 | 52.5 | 58.0 | 90.9 | 126.5 | 95.1 | 110.9 | 88.9 | 48.8 | 77.3 | 124.4 | 111.7 |
DIO |
175.8 | 183.1 | 158.9 | 180.0 | 187.3 | 233.1 | 266.3 | 205.7 | 225.9 | 202.4 | 86.0 | 120.1 | 126.9 |
DPO |
55.8 | 61.2 | 64.6 | 78.5 | 79.8 | 91.4 | 77.9 | 96.3 | 135.0 | 126.2 | 161.7 | 247.9 | 350.8 |
Operating Cycle |
236.7 | 254.6 | 211.4 | 238.0 | 278.2 | 359.5 | 361.4 | 316.6 | 314.8 | 251.2 | 163.3 | 244.5 | 238.6 |
Cash Conversion Cycle |
180.9 | 193.4 | 146.7 | 159.5 | 198.4 | 268.1 | 283.6 | 220.3 | 179.9 | 125.1 | 1.6 | -3.5 | -112.2 |
All numbers in USD currency
Quarterly Financial Ratios Emergent BioSolutions
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-5.08 | - | -1.75 | - | -0.07 | - | -0.61 | 0.09 | 1.31 | 3.51 | 0.75 | 1.76 | -0.24 | 0.91 | 0.84 | -0.18 | -0.51 | -0.07 | 0.42 | 1 | -0.1 | 0.77 | 0.81 | 0.11 | 0.26 | 0.93 | 0.52 | -0.27 | 0.1 | 0.85 | 0.94 | 0.37 | -0.57 | 0.8 | 0.58 | 0.13 | -0.55 | 0.42 | 0.37 | 0.29 | -0.22 | 0.45 | 0.18 | 0.21 | -0.19 | 0.8 | 0.04 | 0.4 | -0.61 |
EBITDA per Share |
-4.45 | - | -0.5 | - | 0.74 | - | -0.38 | 0.55 | 2.33 | 4.86 | 2.77 | 3.48 | 0.32 | 1.5 | 2.97 | 0.93 | -0.02 | - | 1.17 | 1.83 | 0.06 | - | 1.88 | 0.7 | 0.62 | - | 1.57 | 0.39 | 0.76 | 1.27 | 2.29 | 1.01 | -0.52 | 1.18 | 1.47 | 0.62 | -0.51 | 0.64 | 0.87 | 0.64 | -0.26 | 0.67 | 0.48 | 0.37 | -0.28 | 1.28 | 0.23 | 0.69 | -0.95 |
ROE % |
-50.17 | -6.55 | -8.70 | -4.53 | -4.23 | 2.73 | 15.54 | 20.42 | 26.53 | 21.09 | 12.58 | 13.82 | 6.54 | 5.01 | 0.36 | -1.54 | 4.29 | 6.13 | 10.14 | 11.75 | 7.30 | 5.33 | 11.60 | 11.51 | 9.16 | 8.68 | 7.47 | 9.48 | 13.46 | 9.53 | 9.92 | 8.57 | 7.47 | 6.49 | 4.16 | 2.66 | 3.77 | 6.36 | 6.90 | 5.64 | 5.23 | 5.33 | 8.60 | 7.47 | 9.17 | 5.56 | 0.37 | 3.43 | -5.17 |
ROA % |
-20.06 | -3.27 | -4.41 | -2.41 | -2.26 | 1.42 | 7.85 | 10.36 | 13.42 | 10.58 | 6.17 | 6.65 | 3.03 | 2.34 | 0.17 | -0.74 | 1.91 | 2.81 | 6.10 | 8.30 | 6.48 | 4.55 | 8.40 | 7.47 | 5.91 | 5.34 | 4.70 | 6.06 | 8.55 | 6.06 | 6.05 | 4.82 | 4.00 | 3.93 | 3.15 | 2.98 | 4.11 | 4.97 | 5.39 | 4.41 | 4.09 | 4.17 | 6.56 | 5.67 | 6.91 | 4.21 | 0.28 | 2.60 | -3.91 |
ROCE % |
-40.64 | -2.35 | -4.63 | -4.15 | -3.21 | 4.93 | 22.76 | 29.28 | 37.05 | 29.98 | 19.29 | 21.55 | 12.20 | 10.48 | 5.44 | 1.05 | 8.30 | 7.64 | 12.87 | 16.00 | 10.33 | 7.80 | 13.76 | 14.47 | 13.19 | 9.16 | 16.72 | 20.33 | 23.93 | 16.09 | 16.60 | 13.07 | 11.44 | 10.39 | 7.09 | 4.74 | 6.14 | 8.74 | 9.43 | 7.95 | 6.90 | 6.79 | 12.45 | 10.56 | 13.48 | 7.75 | 0.34 | 4.88 | -8.57 |
Current Ratio |
1.6 | 1.8 | 2.0 | - | 2.3 | 2.2 | 2.1 | 2.1 | 2.1 | 2.0 | 2.0 | 2.0 | 2.0 | 1.9 | 1.9 | 1.9 | 1.9 | 1.8 | 1.8 | 1.8 | 1.8 | 6.8 | 6.8 | 6.8 | 6.8 | 2.6 | 2.6 | 2.6 | 2.6 | 2.8 | 2.8 | 2.8 | 2.8 | 2.4 | 2.4 | 2.4 | 2.4 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | 4.2 | 4.2 | 4.2 | 4.2 |
DSO |
63.4 | - | 36.0 | - | 67.7 | - | 71.6 | 51.2 | 55.2 | 36.1 | 54.7 | 53.4 | 118.9 | 68.5 | 79.2 | 101.6 | 127.6 | 88.5 | 138.0 | 108.8 | 157.3 | 67.7 | 87.7 | 130.1 | 110.2 | 83.3 | 88.4 | 138.5 | 111.8 | 65.0 | 67.6 | 87.4 | 128.8 | 36.3 | 38.9 | 48.7 | 101.1 | 56.4 | 62.0 | 67.1 | 165.8 | 92.6 | 131.6 | 124.5 | 154.3 | 62.7 | 115.2 | 76.8 | - |
DIO |
181.9 | - | 163.7 | - | - | - | - | 158.8 | 327.8 | - | 188.0 | 215.8 | 314.1 | - | 188.0 | 201.4 | 212.9 | - | 271.0 | 220.2 | 292.9 | - | 292.8 | 376.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
55.8 | - | 31.3 | - | - | - | - | 58.9 | 127.9 | - | 83.3 | 95.7 | 137.0 | - | 80.1 | 85.8 | 87.2 | - | 106.3 | 86.3 | 102.9 | - | 85.6 | 110.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
245.2 | - | 199.7 | - | 67.7 | - | 71.6 | 210.0 | 383.1 | 36.1 | 242.7 | 269.2 | 433.0 | 68.5 | 267.2 | 303.0 | 340.5 | 88.5 | 409.0 | 328.9 | 450.2 | 67.7 | 380.6 | 506.4 | 110.2 | 83.3 | 88.4 | 138.5 | 111.8 | 65.0 | 67.6 | 87.4 | 128.8 | 36.3 | 38.9 | 48.7 | 101.1 | 56.4 | 62.0 | 67.1 | 165.8 | 92.6 | 131.6 | 124.5 | 154.3 | 62.7 | 115.2 | 76.8 | - |
Cash Conversion Cycle |
189.5 | - | 168.4 | - | 67.7 | - | 71.6 | 151.2 | 255.2 | 36.1 | 159.4 | 173.5 | 296.1 | 68.5 | 187.1 | 217.2 | 253.3 | 88.5 | 302.7 | 242.6 | 347.3 | 67.7 | 294.9 | 396.4 | 110.2 | 83.3 | 88.4 | 138.5 | 111.8 | 65.0 | 67.6 | 87.4 | 128.8 | 36.3 | 38.9 | 48.7 | 101.1 | 56.4 | 62.0 | 67.1 | 165.8 | 92.6 | 131.6 | 124.5 | 154.3 | 62.7 | 115.2 | 76.8 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Emergent BioSolutions , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
- | - | $ 142 M |  USA |
 |
Canopy Growth Corporation
CGC
|
$ 1.7 | 50.0 % | $ 183 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
$ 3.24 | 13.51 % | $ 1.69 B | Canada |
 |
Assertio Holdings
ASRT
|
$ 0.77 | -1.79 % | $ 54.7 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
$ 5.36 | 17.8 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
- | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
- | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
$ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
$ 21.38 | -0.05 % | $ 2.03 B |  France |
 |
Evolus
EOLS
|
$ 6.99 | 1.09 % | $ 433 M | USA |
 |
Harrow Health
HROW
|
$ 47.18 | -7.67 % | $ 1.54 B | USA |
 |
China Pharma Holdings
CPHI
|
$ 1.67 | 11.33 % | $ 29.2 M |  China |
 |
cbdMD
YCBD
|
$ 1.18 | 87.31 % | $ 5.09 M | USA |
 |
Bausch Health Companies
BHC
|
$ 6.95 | -0.93 % | $ 2.54 B | Canada |
 |
OrganiGram Holdings
OGI
|
$ 1.88 | 14.72 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
$ 2.61 | 4.99 % | $ 36.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
$ 4.83 | 1.15 % | $ 636 M | USA |
 |
Pacira BioSciences
PCRX
|
$ 26.28 | 2.14 % | $ 1.22 B | USA |
 |
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
$ 4.12 | -1.67 % | $ 124 M | USA |
 |
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
$ 13.13 | -2.23 % | $ 1.8 B | USA |
 |
ProPhase Labs
PRPH
|
$ 0.12 | -15.26 % | $ 1.9 M | USA |
 |
Radius Health
RDUS
|
- | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
$ 0.93 | -2.37 % | $ 21.7 M | USA |
 |
Sundial Growers
SNDL
|
$ 2.19 | 24.01 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
- | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
$ 0.64 | -0.02 % | $ 30.6 M | USA |
 |
Solid Biosciences
SLDB
|
$ 5.85 | -0.34 % | $ 239 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
$ 3.59 | -3.37 % | $ 4.46 M | USA |
 |
Tricida
TCDA
|
- | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
$ 11.86 | 40.68 % | $ 7.33 B | Canada |
 |
TherapeuticsMD
TXMD
|
$ 1.79 | -2.72 % | $ 18.7 M | USA |
 |
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | USA |
 |
Veru
VERU
|
$ 2.45 | -4.3 % | $ 330 M | USA |
 |
Viatris
VTRS
|
$ 11.63 | 0.3 % | $ 14.1 B | USA |